Search

Your search keyword '"B Ataseven"' showing total 15 results

Search Constraints

Start Over You searched for: Author "B Ataseven" Remove constraint Author: "B Ataseven" Topic business Remove constraint Topic: business
15 results on '"B Ataseven"'

Search Results

1. 382 Molecular classification of endometrial carcinoma substantially changing risk-assessment: Results from a european multicentre initiative

2. 930 Comparison of clinicopathological characteristics and survival outcomes of patients with grade III endometrioid adenocarcinoma and carcinosarcoma

3. 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

4. Management of the axilla for high-risk early breast cancer (EBC) before and after neoadjuvant chemotherapy (NACT): an analysis of the multicentre GeparOcto trial

5. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

6. Vaginale Hysterektomie und beidseitige Adnexektomie in interdisziplinärem Konzept bei Frau zu Mann – Transsexualismus

7. P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer

8. Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability

10. Primary cerebral metastasis in bilateral breast cancer

11. 63P Phase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients

12. 1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

13. Safeher: A Study of Assisted- and Self-Administered Subcutaneous Trastuzumab (H-SC) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (EBC)

15. O-44 Evaluation of estrogen and progesterone receptor, Her-2 and Topo IIα in primary breast cancer and metastatic axillary lymph nodes

Catalog

Books, media, physical & digital resources